|
시장보고서
상품코드
1298009
경피적 중추신경계(CNS) 치료제 시장(-2028년)Transdermal CNS Therapeutics to 2028 |
||||||
경피적 중추신경계(CNS) 치료제 시장에 대해 조사했으며, 시장 개요와 함께 기술 동향, 수요 촉진요인, 부문별 약물 동향, 시장 진입 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
- 주요 요약
- 2028년까지 경피적 중추신경계 치료제
- 시장 기회
- 경피 약물전달 역학
- 수요 촉진요인
- 패치 제조 역학
- 박리 라이너
- 배킹 필름
- 반투막
- 접착제
- 경피적 중추신경계 치료제 시장
- ADHD
- 데이트라나
- 메틸페니데이트(Daytrana - Noven)
- 알츠하이머병
- 리바스티그민(Exelon - Novartis)
- 아리셉트 경피 흡수제 - 최근의 활동
- 엑셀론
- 우울증
- 항우울제
- 셀레길린(EMSAM - Mylan)
- 메스꺼움
- 알칼로이드
- 스코폴라민(Transderm Scop) GlaxoSmithKline Consumer Health
- 그라니세트론(Sancuso - ProStrakan)
- 파킨슨병
- 레보도파
- 로티고틴(Neupro - Schwarz/UCB))
- 정신분열증
- 아세나핀(Secuado - Noven)
- 경피적 중추신경계 의약품 분석과 시장 평가
- FDA 승인 경피적 중추신경계 처방 제품
- 중추신경계 흥분제
- AChE 억제제
- 비정형 항정신병제
- 알칼로이드
- 도파민 작용제
- 5-HT3 수용체 길항제
- MAO 억제제
- 전략적 요인과 브랜딩 문제
- 도파민 작용제
- 기업 개요
“Transdermal CNS Therapeutics to 2028: Products, Therapeutics, Markets and Forecasts” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, patch designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for Transdermal patches Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Converging Factors Driving Growth in Transdermal Delivery
Transdermal CNS drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Growth in demand for drug patches is being driven by several factors - factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs will keep this segment expanding through 2028.
What You Will Learn:
- Analyzes and evaluates current transdermal CNS therapeutics markets and products and assesses the market potential for existing and probable future products
- Analyzes patch designs, technologies and patch development issues
- Profiles patch manufacturers and third-party transdermal supply chain companies
- Provides detailed assessments of more than a dozen products in more than a dozen product categories
- Provides market data and forecasts to 2028
- Profiles transdermal drug patch product providers, their product development activity, and strategies
- Evaluates the impact of economic, technology, and regulatory factors
Table of Contents
- Executive Summary
- Transdermal CNS Therapeutics to 2028
- The Market Opportunity
- Transdermal Drug Delivery Dynamics
- Demand Drivers
- Patch Manufacturing Dynamics
- Release Liners
- Backing Films
- Semi-permeable Membranes
- Adhesives
- Markets for Transdermal CNS Therapeutics
- ADHD
- Daytrana
- Methylphenidate (Daytrana - Noven)
- Alzheimer's Disease
- Rivastigmine (Exelon - Novartis)
- Aricept Transdermal - Recent Activity
- Exelon
- Depression
- Antidepressants
- Selegiline (EMSAM - Mylan)
- Nausea
- Alkaloids
- Scopolamine (Transderm Scop) GlaxoSmithKline Consumer Health
- Granisetron (Sancuso - ProStrakan)
- Parkinson's Disease
- Levodopa
- Rotigotine (Neupro - Schwarz/UCB))
- Schizophrenia
- Asenapine (Secuado - Noven)
- Transdermal CNS Drug Product Analysis and Market Assessments
- FDA Approved Transdermal CNS Prescription Products
- CNS Stimulants
- AChE Inhibitors
- Atypical Antipsychotics
- Alkaloids
- Dopamine Agonists
- 5-HT3 Receptor Antagonists
- MAO Inhibitors
- Strategic Factors and Branding Issues
- Dopamine Agonists
- Company Profiles
